Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹39,698 Cr
Revenue (TTM)
₹15,262 Cr
Net Profit (TTM)
₹1,013 Cr
ROE
7 %
ROCE
7 %
P/E Ratio
39.2
P/B Ratio
1.8
Industry P/E
37.02
EV/EBITDA
12.2
Div. Yield
0.2 %
Debt to Equity
0.6
Book Value
₹180.3
EPS
₹8.2
Face value
5
Shares outstanding
1,200,600,000
CFO
₹11,463.80 Cr
EBITDA
₹13,147.40 Cr
Net Profit
₹7,739.70 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biocon
| -9.5 | -0.9 | 2.6 | 7.4 | -0.9 | -1.1 | 16.1 |
|
BSE Healthcare
| -5.9 | 0.5 | 7.3 | 18.6 | 22.8 | 22.3 | 9.5 |
|
BSE Mid Cap
| -3.3 | 3.7 | 11.1 | 3.9 | 25.8 | 31.8 | 15.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Biocon
| 43.0 | -4.7 | -28.2 | -21.7 | 58.0 | -6.1 | 16.9 |
|
BSE Mid Cap
| 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 | -13.3 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biocon
|
330.8 | 39,697.8 | 15,261.7 | 1,429.4 | 9.5 | 4.6 | 39.2 | 1.8 |
| 2,574.9 | 32,180.5 | 4,648.1 | 920.4 | 24.0 | 24.7 | 35 | 8.5 | |
| 2,192.8 | 16,674.3 | 1,937.5 | 541.1 | 30.0 | 19.9 | 31.1 | 5.8 | |
| 1,484.2 | 1,19,898.3 | 27,547.6 | 5,291.1 | 21.9 | 17.7 | 22.7 | 3.8 | |
| 1,504.3 | 20,527.9 | 2,893.6 | 375.0 | 24.3 | 12.5 | 58.3 | 7.2 | |
| 3,020.9 | 51,186.9 | 3,749.2 | 927.6 | 29.6 | 51 | 55.2 | 26.2 | |
| 1,702.0 | 26,521.7 | 3,918.0 | 659.6 | 22.0 | 19.9 | 40.2 | 7.7 | |
| 5,147.8 | 23,551.4 | 2,281.4 | 767.6 | 29.8 | 15.9 | 30.7 | 5.6 | |
| 6,275.5 | 14,425.2 | 2,038.3 | 396.4 | 24.0 | 48.7 | 39.9 | 15.8 | |
| 1,683.6 | 4,03,868.1 | 52,578.4 | 10,980.1 | 23.3 | 16.2 | 37 | 5.6 |
1 min read•By Research Desk
2 min read•By Value Research
5 min read•By Research Desk
2 min read•By Research Desk
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics,... Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India. Read more
Incorporated
1978
Chairman
Kiran Mazumdar-Shaw
Managing Director
Siddharth Mittal
Headquarters
Bengaluru, Karnataka
Website
Looking for more details about Biocon Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsTranscript Of Earnings Call Q4 FY25
15-May-2025Notification To Stock Exchange
15-May-2025
The total asset value of Biocon Ltd stood at ₹ 58,797 Cr as on 31-Mar-25
The share price of Biocon Ltd is ₹330.75 (NSE) and ₹330.65 (BSE) as of 23-May-2025 IST. Biocon Ltd has given a return of -0.92% in the last 3 years.
Biocon Ltd has a market capitalisation of ₹ 39,698 Cr as on 23-May-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Biocon Ltd is 1.83 times as on 23-May-2025, a 66% discount to its peers’ median range of 5.35 times.
The P/E ratio of Biocon Ltd is 39.18 times as on 23-May-2025, a 6% premium to its peers’ median range of 37.02 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Biocon Ltd and enter the required number of quantities and click on buy to purchase the shares of Biocon Ltd.
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
The promoters of Biocon Ltd are KIRAN MAZUMDAR SHAW and GLENTEC INTERNATIONAL. They collectively own 60.12 per cent of the total equity. The chairman of the company is Kiran Mazumdar-Shaw
There is no promoter pledging in Biocon Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
51,187
|
|
|
32,180
|
|
|
26,522
|
|
|
23,551
|
|
|
20,528
|
|
|
16,674
|
|
|
14,425
|
|
|
4,03,868
|
|
|
1,19,898
|
| Biocon Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
4.61
|
|
Operating margin(%)
|
9.49
|
|
Net Margin(%)
|
8.66
|
|
Dividend yield(%)
|
0.15
|
Yes, TTM profit after tax of Biocon Ltd was ₹1,013 Cr.
₹-2.35
(
